How to buy ResMed (RMD) shares

Learn how to easily invest in ResMed shares.

ResMed
AU: RMD - AUD
A$36.09
+ A$0.44 ( + 1.23%)
MEDICAL INSTRUMENTS & SUPPLIES

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

ResMed Inc is a medical instruments & supplies business based in Australia. ResMed shares (RMD) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. ResMed has a trailing 12-month revenue of around $3.3 billion. If you're looking to buy shares, check out the steps below.

How to buy shares in ResMed

  1. Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
  3. Search for ResMed. Find the share by name or ticker symbol: RMD. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until ResMed reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
  6. Check in on your investment. Congratulations, you own a part of ResMed. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

ResMed stock price (ASX:RMD)

Use our graph to track the performance of RMD stocks over time.

ResMed shares at a glance

Information last updated 2021-11-28.
52-week range$23.3892 - $40.7414
50-day moving average $36.0046
200-day moving average $31.8477
Target price$38.63
PE ratio 29.4596
Dividend yield $1.62 (4.57%)
Earnings per share (TTM) $1.1983

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Name Product Standard brokerage fee Inactivity fee Markets
IG Share Trading
AUD $8 or 0.1%
$50 per quarter if you make fewer than three trades in that period
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Superhero share trading
$5
No
ASX shares, US shares
Earn up to 15,000 Qantas frequent flyer points when you transfer an exisiting balance or trade. Offer valid for all new and existing Superhero members until 28 February.
Pay zero brokerage on US stocks and all ETFs and just $5 (flat fee) to trade Australian shares from your mobile or desktop.
ThinkMarkets Share Trading
AUD $8
No
ASX shares
Limited-time offer: Get 10 free ASX trades ($0 brokerage) when you open a share trading account with ThinkMarkets before 31 December 2021(T&Cs apply). $8 flat fee brokerage for CHESS Sponsored ASX stocks (HIN ownership), plus free live stock price data on an easy to use mobile app.
Bell Direct Share Trading
AUD $15
No
ASX shares, mFunds, ETFs
Finder Exclusive: Get 5 free stock trades and unlimited ETF trades until 31 Dec 2021, when you join Bell Direct. T&Cs apply.
Bell Direct offers a one-second placement guarantee on market-to-limit ASX orders or your trade is free, plus enjoy extensive free research reports from top financial experts.
Saxo Capital Markets (Classic account)
AUD $5
No
ASX shares, Global shares, ETFs
Access 19,000+ stocks on 40+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
loading

Compare up to 4 providers

Is it a good time to buy ResMed stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

ResMed price performance over time

Historical closes compared with the last close of A$36.09

1 week (2021-11-25) 1.75%
1 month (2021-11-05) 1.15%
3 months (2021-09-03) -8.17%
6 months (2021-06-04) 34.46%
1 year (2020-12-04) 29.49%
2 years (2019-12-04) 65.63%
3 years (2018-12-04) 137.90%
5 years (2016-12-02) 350.56%

Is ResMed under- or over-valued?

Valuing ResMed stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ResMed's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

ResMed's P/E ratio

ResMed's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 29x. In other words, ResMed shares trade at around 29x recent earnings.

That's relatively low compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

ResMed's PEG ratio

ResMed's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.7308. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into ResMed's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

ResMed's EBITDA

ResMed's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.1 billion (£0.0 million).

The EBITDA is a measure of a ResMed's overall financial performance and is widely used to measure a its profitability.

ResMed financials

Revenue TTM $3.3 billion
Operating margin TTM 28.74%
Gross profit TTM $1.9 billion
Return on assets TTM 12.87%
Return on equity TTM 17.52%
Profit margin 14.92%
Book value 5.1918
Market capitalisation $51.6 billion

TTM: trailing 12 months

ResMed share dividends

85%

Dividend payout ratio: 85.26% of net profits

Recently ResMed has paid out, on average, around 85.26% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.65% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), ResMed shareholders could enjoy a 0.65% return on their shares, in the form of dividend payments. In ResMed's case, that would currently equate to about A$1.62 per share.

ResMed's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

The latest dividend was paid out to all shareholders who bought their shares by 9 November 2021 (the "ex-dividend date").

Have ResMed's shares ever split?

ResMed's shares were split on a 2:1 basis on 11 August 2010. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your ResMed shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for ResMed shares which in turn could have impacted ResMed's share price.

ResMed share price volatility

Over the last 12 months, ResMed's shares have ranged in value from as little as $23.3892 up to $40.7414. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while ResMed's is 0.2951. This would suggest that ResMed's shares are less volatile than average (for this exchange).

ResMed overview

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; and connectivity module and propeller solutions. In addition, it offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice agencies, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

ResMed in the news

There are no recent company news

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs comes with a higher risk of losing money rapidly due to leverage. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site